Statins and nonalcoholic fatty liver disease: a bright future?

被引：16

作者：

Athyros, Vasilios G. ^{[1
]}

Katsiki, Niki ^{[1
]}

Karagiannis, Asterios ^{[1
]}

Mikhailidis, Dimitri P. ^{[2
]}

机构：

[1] Aristotle Univ Thessaloniki, Hippokrat Hosp, Sch Med, Propedeut Dept Internal Med 2, GR-54006 Thessaloniki, Greece

[2] UCL, Sch Med, Dept Clin Biochem, London NW3 2QG, England

来源：

EXPERT OPINION ON INVESTIGATIONAL DRUGS | 2013年 / 22卷 / 09期

关键词：

cardiovascular disease; inflammasomes; microparticles; nonalcoholic fatty liver disease; statins;

D O I：

10.1517/13543784.2013.824423

中图分类号：

R9 [药学];

学科分类号：

1007 ;

摘要：

Nonalcoholic fatty liver disease (NAFLD) is the most common liver disease affecting up to 30% of adults in Western countries. NAFLD and mainly nonalcoholic steatohepatitis (NASH) are independent cardiovascular disease (CVD) risk factors; more of these patients are expected to die from CVD rather than from liver disease. The effect of statins on newer risk factors that may influence the pathobiology of liver damage in NASH is considered. These include microparticles, inflammasomes, gut-liver axis abnormalities and dietary lipids. Evidence suggests that statins induce NAFLD/NASH resolution and substantially improve symptom-free survival from CVD to a greater extent than in patients without NAFLD. However, large randomized clinical trials are needed to verify these findings.

引用

页码：1089 / 1093

页数：5

共 21 条

[1]

Antonopoulos AS, 2012, CURR PHARM DESIGN, V18, P1519

[2] Do we need to consider inflammatory markers when we treat atherosclerotic disease? [J].

Athyros, Vasilios G. ;

Kakafika, Anna I. ;

Karagiannis, Asterios ;

Mikhailidis, Dimitri P. .

ATHEROSCLEROSIS, 2008, 200 (01) :1-12

[3] Effect of multifactorial treatment on non-alcoholic fatty liver disease in metabolic syndrome: a randomised study [J].

Athyros, Vasilios G. ;

Mikhailidis, Dimitri P. ;

Didangelos, Triandafillos P. ;

Giouleme, Olga I. ;

Liberopoulos, Evangelos N. ;

Karagiannis, Asterios ;

Kakafika, Anna I. ;

Tziomalos, Konstantinos ;

Burroughs, Andrew K. ;

Elisaf, Moses S. .

CURRENT MEDICAL RESEARCH AND OPINION, 2006, 22 (05) :873-883

[4] Statin-based treatment for cardiovascular risk and non-alcoholic fatty liver disease. Killing two birds with one stone? [J].

Athyros, Vasilios G. ;

Tziomalos, Konstantinos ;

Daskalopoulos, Georgios N. ;

Karagiannis, Asterios ;

Mikhailidis, Dimitri P. .

ANNALS OF MEDICINE, 2011, 43 (03) :167-171

[5] Safety and efficacy of long-term statin treatment for cardiovascular events in patients with coronary heart disease and abnormal liver tests in the Greek Atorvastatin and Coronary Heart Disease Evaluation (GREACE) Study: a post-hoc analysis [J].

Athyros, Vasilios G. ;

Tziomalos, Konstantinos ;

Gossios, Thomas D. ;

Griva, Theodora ;

Anagnostis, Panagiotis ;

Kargiotis, Konstantinos ;

Pagourelias, Efstathios D. ;

Theocharidou, Eleni ;

Karagiannis, Asterios ;

Mikhailidis, Dimitri P. .

LANCET, 2010, 376 (9756) :1916-1922

[6] Safety and impact in cardio vascular events of long-term multifactorial treatment in patients with metabolic syndrome and abnormal liver function tests: a post hoc analysis of the randomised ATTEMPT study [J].

Athyros, Vassilios G. ;

Giouleme, Olga ;

Ganotakis, Emmanouel S. ;

Elisaf, Moses ;

Tziomalos, Konstantinos ;

Vassiliadis, Themistoklis ;

Liberopoulos, Evangelos N. ;

Theocharidou, Eleni ;

Karagiannis, Asterios ;

Mikhailidis, Dimitri P. .

ARCHIVES OF MEDICAL SCIENCE, 2011, 7 (05) :796-805

[7] Cell-derived microparticles in atherosclerosis: biomarkers and targets for pharmacological modulation? [J].

Baron, Morgane ;

Boulanger, Chantal M. ;

Staels, Bart ;

Tailleux, Anne .

JOURNAL OF CELLULAR AND MOLECULAR MEDICINE, 2012, 16 (07) :1365-1376

[8] NASH and atherosclerosis are two aspects of a shared disease: Central role for macrophages [J].

Bieghs, Veerle ;

Rensen, Patrick C. N. ;

Hofker, Marten H. ;

Shiri-Sverdlov, Ronit .

ATHEROSCLEROSIS, 2012, 220 (02) :287-293

[9] Fatty Acid and Endotoxin Activate Inflammasomes in Mouse Hepatocytes that Release Danger Signals to Stimulate Immune Cells [J].

Csak, Timea ;

Ganz, Michal ;

Pespisa, Justin ;

Kodys, Karen ;

Dolganiuc, Angela ;

Szabo, Gyongyi .

HEPATOLOGY, 2011, 54 (01) :133-144

[10] Novel therapeutic targets for nonalcoholic fatty liver disease [J].

Eguchi, Akiko ;

Povero, Davide ;

Alkhouri, Naim ;

Feldstein, Ariel E. .

EXPERT OPINION ON THERAPEUTIC TARGETS, 2013, 17 (07) :773-779

← 1 2 3 →